Piper Sandler Maintains Overweight on Connect Biopharma Hldgs, Lowers Price Target to $5
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Piper Sandler analyst Biren Amin maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight and lowers the price target from $7 to $5.
Piper Sandler analyst Biren Amin maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight and lowers the price target from $7 to $5.
